An observational study in Cirrhosis, Liver, sponsored by Instituto de Investigación Marqués de Valdecilla. Recruiting at 11 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Instituto de Investigación Marqués de Valdecilla · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Liver Cirrhosis with a site in Spain — 16 open to participants now, 20 under way, 3 of them phase 3. Liver Cirrhosis · Spain.
Among the 76 studies in Liver Cirrhosis with a site in Spain, this one is the 14th largest by planned enrollment of the 26 observational ones that give a count, is one of 2 that started in 2025, is one of 26 observational ones, reaches primary completion later than 12 of the 19 other live ones, and was the 74th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →16 of the 76 studies in Liver Cirrhosis with a site in Spain are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Spain, Austria, Belgium and 9 more countries
Ages 18+
Boehringer Ingelheim · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
Hospital General Universitario Gregorio Marañon · Sites in Spain
Ages 50–75
The Cleveland Clinic · Sites in Spain, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
European Foundation for Study of Chronic Liver Failure · Sites in Spain, France, Germany and 2 more countries
Ages 18–80
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 27 · Phase 3 14 · Phase 4 7
First in 1993; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 76 across the 50 interventional studies, 334 across the 26 observational. Of the 47 that completed or were terminated, 13 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 76 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Marqués de Valdecilla is the lead sponsor of 34 studies on the registry; 12 are open to participants now.
Instituto de Investigación Marqués de Valdecilla has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Liver Cirrhosis with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04971577Phase 3Anna CrucetaEfficacy of Simvastatin in Alcoholic Liver Fibrosis | 2027-03 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07658755Hospital General Universitario Gregorio MarañonAutomated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme | 2027-06-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 76 studies in Liver Cirrhosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The assessment of post-procedural bleeding risk in cirrhosis remains a clinical challenge due to the lack of precise predictive tools and its high associated mortality. Although guidelines recommend a restrictive transfusion policy, adherence remains low, with a high rate of prophylactic transfusions despite unclear benefits. This multicenter, prospective, and observational study will evaluate the utility of ROTEM in bleeding risk stratification for cirrhotic patients with significant abnormalities in conventional hemostasis tests undergoing high-risk invasive procedures. The primary objective is to establish cut-off values with a high negative predictive value, optimizing transfusion decisions and reducing unnecessary blood product use. Additionally, the study will analyze the relationship between ROTEM, inflammation biomarkers, and coagulation factors, along with a cost-effectiveness analysis comparing different transfusion strategies. This will be the largest study to date assessing ROTEM in this setting, overcoming the limitations of previous studies, which have been mostly retrospective with heterogeneous populations and procedures. Its findings could contribute to the standardization of transfusion management in cirrhosis and improve healthcare resource efficiency. The widespread availability of ROTEM in other disciplines within the National Health System will facilitate its implementation in this clinical setting without requiring additional investment in equipment.
patients with cirrhosis undergoing invasive procedures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cirrhosis undergoing invasive procedures
Device: Rotational thromboelastometry
rotem
Incidence of post-procedural bleeding events within 28 days
Number of participants with bleeding events occurring within 28 days after undergoing a high-risk invasive procedure. Bleeding will be classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. ROTEM parameters (Clotting Time \[CT\], Clot Formation Time \[CFT\], Amplitude at 5/10 minutes \[A5, A10\], Maximum Clot Firmness \[MCF\], Maximum Lysis \[ML\], and Lysis Index at 30 minutes \[LI30\]) will be measured pre-procedure and analyzed to determine cut-off values with high negative predictive value for post-procedural bleeding.
Time frame: 28 days after the procedure
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Feb 2028, 35 months after the start.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 35 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Marqués de Valdecilla